FTSE MIB
34.657,35 +318,03 (+0,93%) Dow Jones
39.512,84 +125,08 (+0,32%) Nasdaq
16.340,87 -5,40 (-0,03%) Nikkei 225
38.229,11 +155,13 (+0,41%) Petrolio
78,20 -1,06 (-1,34%) Bitcoin EUR
56.258,81 -1.821,60 (-3,14%)
EyePoint Pharmaceuticals, Inc. (EYPT)
Dopo ore:
| Chiusura precedente | 12,67 |
| Aperto | 12,80 |
| Denaro | 12,00 x 100 |
| Lettera | 12,11 x 400 |
| Min-Max giorno | 11,97 - 12,90 |
| Intervallo di 52 settimane | 5,67 - 30,99 |
| Volume | |
| Media Volume | 1.173.712 |
| Capitalizzazione | 629,697M |
| Beta (5 anni mensile) | 1,72 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -1,82 |
| Prossima data utili | 31 lug 2024 - 05 ago 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 40,78 |
GlobeNewswireEyePoint Pharmaceuticals Strengthens Board and Executive Leadership Team
– Stuart Duty appointed to EyePoint’s Board of Directors – – George Elston promoted to Executive Vice President – WATERTOWN, Mass., Oct. 16, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with retinal diseases, today announced the appointment of Stuart Duty to its Board of Directors and the promotion of George Elston to Executive Vice President. “We are excited to welcome
- GlobeNewswire
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
WATERTOWN, Mass., Sept. 18, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). The Company granted stock options to purchase up to an ag
- GlobeNewswire
EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences
WATERTOWN, Mass., Aug. 30, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced that the Company will participate at the following upcoming conferences: Citi's 18th Annual BioPharma ConferenceForum: 1x1 Investor MeetingsDate: Wednesday, September 6, 2023 H.C. Wainwright 25th Annual Global Investment ConferenceForum: Corp
